Several other drugmakers, Novo among them, abandoned their attempts to make inhalable insulin in the wake of Exubera's failure.
Delivering insulin through the stomach should be ideal: insulin would travel directly to the liver, its primary site of action, in a way that mimics the action of endogenous insulin.